Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 16/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126960 | 0.84 | FGFR3 (0.57) | FGFR3F10 | |
| SCHEMBL12678267 | 0.79 | FGFR3 (0.85) | FGFR3F10 | |
| SCHEMBL1127005 | 0.77 | MITF (0.55) | FGFR3 | |
| SCHEMBL17023156 | 0.72 | FGFR3 (0.42) | FGFR3F10 | |
| SCHEMBL3349886 | 0.71 | FGFR3 (0.59) | FGFR3 | |
| SCHEMBL1126317 | 0.71 | FGFR3 (1.00) | FGFR3F10 | |
| SCHEMBL1126897 | 0.70 | L3MBTL1 (0.58) | FGFR3 | |
| SCHEMBL1127056 | 0.68 | FGFR3 (0.62) | FGFR3 | |
| SCHEMBL12678289 | 0.67 | FGFR3 (0.74) | FGFR3F10 | |
| SCHEMBL17023017 | 0.67 | FGFR3 (0.65) | FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885EP300 1352/4885F10 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.